Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J0791 |
Short Description | Inj crizanlizumab-tmca 5mg |
Long Description | Injection, crizanlizumab-tmca, 5 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2020-07-01 |
Date Added | 2020-07-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
00078088361 | J0791 | Inj crizanlizumab-tmca 5mg | Adakveo | NOVARTIS PHARMACEUTICALS CORPORATION | 5 MG | 10 | 1 | 20 | 20 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 5 MG |
HCPCS/CPT Billing Units | 0.2 |
Total doses ordered | |
Billing Units | 0.2 |
Drug Details
-
Crizanlizumab-tmca injection is used to reduce the number of pain crises (sudden, severe pain that may last several hours to several days) in adults and children 16 years of age and older with sickle cell disease (an inherited blood disease). Crizanlizumab-tmca is in a class of medications called monoclonal antibodies. It works by blocking certain blood cells from interacting.